SHIPRA GANDHI

Employment

• Emory University
  2025 - Present
• Roswell Park Comprehensive Cancer Center Staff Physician
  2018 - 2025

Education

Education history is unavailable.

Projects & Funding

Projects & funding information is unavailable.

Publications (83)

• Data from Computationally Derived Spatial Immune Signature Identifies Trastuzumab Responders in HER2+ Breast Cancer: NSABP B-41 Clinical Trial Validation
  2026 DOI: 10.1158/1078-0432.c.8536790
  +Save
• Supplementary Data1 from Computationally Derived Spatial Immune Signature Identifies Trastuzumab Responders in HER2+ Breast Cancer: NSABP B-41 Clinical Trial Validation
  2026 DOI: 10.1158/1078-0432.32675237
  +Save
• Is more always better? Low-dose pembrolizumab as a practical step toward more equitable triple-negative breast cancer care
  Annals of Oncology 2026 DOI: 10.1016/j.annonc.2026.02.005
  +Save
• Computationally Derived Spatial Immune Signature Identifies Trastuzumab Responders in HER2+ Breast Cancer: NSABP B-41 Clinical Trial Validation
  Clinical Cancer Research 2026 DOI: 10.1158/1078-0432.CCR-25-4185
  +Save
• Mutational landscape of triple-negative breast cancer in African American women
  Nature Genetics 2025 DOI: 10.1038/s41588-025-02322-y
  +Save
• Real-World Clinical Outcomes With Sacituzumab Govitecan in Metastatic Triple-Negative Breast Cancer
  JCO Oncology Practice 2025 DOI: 10.1200/OP.24.00242
  +Save
• Racial disparities in clinical outcomes of early-stage triple-negative breast cancer treated with neoadjuvant chemoimmunotherapy: Insights from the NCDB.
  Journal of Clinical Oncology 2025 DOI: 10.1200/JCO.2025.43.16_suppl.602
  +Save
• Racial and ethnic disparities in clinical outcomes of HER2-positive metastatic breast cancer treated with antibody-drug conjugates: A TriNetX real-world evidence study
  Journal of Clinical Oncology 2025 DOI: 10.1200/JCO.2025.43.16_suppl.1036
  +Save
• Paclitaxel, interferons and functional reprogramming of tumor-associated macrophages in optimized chemo-immunotherapy
  Journal for Immunotherapy of Cancer 2025 DOI: 10.1136/jitc-2024-010960
  +Save
• Immune checkpoint inhibitor (ICI) efficacy in triple-negative breast cancer (TNBC) patients with liver metastases (LM): A meta-analysis
  Journal of Clinical Oncology 2025 DOI: 10.1200/JCO.2025.43.16_suppl.e13131
  +Save